Incyte (INCY) Restructuring Costs (2010 - 2016)

Incyte's (INCY) quarterly Restructuring Costs came in at $1.6 million in Q4 2016, up 6.67% on a QoQ basis from $1.5 million in Q3 2016.

Incyte (INCY) Restructuring Costs (2010 - 2016) Analysis & Trends

Incyte (INCY) has 3 years of Restructuring Costs data on file, last reported at $1.6 million in Q4 2016.

Quarterly Restructuring Costs changed N/A year-over-year to $1.6 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $4.4 million (changed N/A YoY) and the FY2016 annual result came in at $1.6 million, changed N/A from the prior year.
Restructuring Costs improved to $1.6 million in Q4 2016, from $1.5 million in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $1.6 million in Q4 2016 to a low of $1.3 million in Q2 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Incyte	24.15 Bn	19.61 Bn	1.57 Bn

Download Data